Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells
Tóm tắt
Both tamoxifen and medroxyprogesterone acetate have a direct antitumor effect and are widely used in breast cancer therapy. Luteinizing-hormone-releasing hormone analogs inhibit the growth of breast cancer cells and could represent an alternative treatment for patients affected by breast cancer. Our study was carried out to investigate the effect of leuprorelin (TAP-144) alone or combined with tamoxifen or medroxyprogesterone acetate in human breast cancer cells. Ineffective when used in the absence of estrogens, TAP-144 inhibited the estrogen-stimulated growth of MCF-7, CG-5 and ZR-75-1 cells cultured in medium supplemented with charcoaltreated serum. The growth of estrogen-unresponsive MDA-MB-231 cells was not affected by TAP-144. The combination of TAP-144 with tamoxifen in CG-5 cells did not determine any enhancement of inhibition of cell growth, whereas in both CG-5 and MCF-7 cells, when 1 μM TAP-144 was associated with 0.1 μM medroxyprogesterone acetate, cell growth inhibition was increased, resulting in a subadditive effect. Progesterone receptor levels of CG-5 cells were significantly increased by TAP-144 in the presence of 17β-estradiol with respect to those present in control and 17β-estradiol-treated cells.
Tài liệu tham khảo
Blankenstein MA, Henkelman MS, Klijn JGM (1985) Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 21:1493–1499
Cailleau R, Young R, Olivè M, Reeves WJ Jr (1974) Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53:661–664
Crighton IL, Dowsett M, Lal A, Man A, Smith IE (1989) Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects. Br J Cancer 60:644–648
Denz H, Lechleitner M, Marth Ch, Daxenbichler G, Gastl G, Braunsteiner H (1985) Effect of human recombinant alpha-2-and gammainterferon on the growth of human cell lines from solid tumors and hematologic malignancies. J Interferon Res 5:147–157
Eidne KA, Flanagan CA, Harris NS, Millar RP (1987) Gonadotropin releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64:425–432
Eisenberger MA, O'Dwyer PJ, Fridman MA (1986) Gonadotropin hormone releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Oncol 4:414–424
Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ (1978) Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 38:3352–3364
Foekens JA, Henkelman MS, Fukkink JF, Blankenstein MA, Klijn JGM (1986) Combined effects of buserelin, estradiol and tamoxifen on the growth of MCF-7 human breast cancer cells in vitro. Biochem Biophys Res Commun 140:550–556
Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y (1987) Proliferation, hormonal responsiveness and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47:4355–4360
Klijn JGM, Foekens JA (1987) Long-term peptide hormone treatment with LHRH-agonists in metastatic breast cancer: a review. In: Klijn JGM (ed) Diagnosis and treatment of pituitary tumors: a starting point for manipulation of cancer with hypothalamic hormones. Erasmus University, Rotterdam, pp 275–289
Klijn JGM, Jong FH de, Lamberts SWJ, Blankenstein MA (1985) GNRH agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23:867–873
Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM (1985) Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313:231–233
Mullen P, Scott WN, Miller WR (1991) Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br J Cancer 63:930–932
Natoli C, Sica G, Natoli V, Serra A, Iacobelli S (1983) Two new estrogen supersensitive variants of the MCF-7 human breast cancer cell line. Breast Cancer Res Treat 3:23–32
Neri C, Berthois Y, Schatz B, Drieu K, Martin PM (1990) Compared effects of GnRH analogs and 4-hydroxytamoxifen on growth and steroid receptors in antiestrogen sensitive and resistant MCF-7 breast cancer cell sublines. Breast Cancer Res Treat 15:85–93
Nicholson RI and Walker KJ (1989) Gn-RH agonists in breast and gynaecologic cancer treatment. J Steroid Biochem 33:801–804
Plowman PN, Nicholson RI, Walker KJ (1986) Remissions of post menopausal breast cancer during treatment with the luteinizing hormone releasing hormone agonist ICI 118630. Br J Cancer 54:903–909
Scambia G, Benedetti Panici P, Baiocchi G, Perrone L, Gaggini C, Iacobelli S, Mancuso S (1988) Growth inhibitory effect of LH-RH analogs on human breast cancer cells. Anticancer Res 8:187–190
Schally AV, Redding TW, Comaru-Schally AM (1984) Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep 68:281–289
Scott WN, Mullen P, Miller WR (1991) Factors influencing the response of MCF-7 cells to an agonist of luteinising hormone-releasing hormone. Eur J Cancer 27:1458–1461
Sharoni Y, Bosin E, Miinster A, Levy J, Schally AV (1989) Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86:1648–1651
Soule HD, Vasquez J, Long A, Alberts BM (1973) A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51:1409–1416
Wilding G, Chen M, Gelmann EP (1987) LHRH agonists and human breast cancer cells. Nature 329:770